Stockscreener 앱 받기
100.02
2.17%
-2.25
전일 마감가:
$102.27
열려 있는:
$102.175
하루 거래량:
9.23M
Relative Volume:
3.05
시가총액:
$33.18B
수익:
$18.08B
순이익/손실:
$1.81B
주가수익비율:
16.94
EPS:
5.904
순현금흐름:
$2.10B
1주 성능:
-17.08%
1개월 성능:
-18.38%
6개월 성능:
-23.25%
1년 성능:
-25.19%
1일 변동 폭
$99.60
$102.75
1주일 범위
$99.60
$123.09
52주 변동 폭
$99.60
$150.45
킴벌리클라크 Stock (KMB) Company Profile
명칭
Kimberly Clark Corp
전화
(972) 281-1200
주소
351 PHELPS DRIVE, IRVING, TX
KMB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KMB
Kimberly Clark Corp
|
100.02 | 33.94B | 18.08B | 1.81B | 2.10B | 5.904 |
|
PG
Procter Gamble Co
|
146.61 | 345.88B | 84.93B | 16.86B | 14.94B | 6.8506 |
|
UL
Unilever Plc Adr
|
60.66 | 148.76B | 64.99B | 6.71B | 6.53B | 2.4355 |
|
CL
Colgate Palmolive Co
|
75.80 | 60.44B | 20.10B | 3.04B | 3.37B | 3.569 |
|
KVUE
Kenvue Inc
|
16.20 | 30.92B | 15.14B | 1.42B | 1.63B | 0.7361 |
킴벌리클라크 Stock (KMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-18 | 재개 | Piper Sandler | Overweight |
| 2025-01-08 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-23 | 개시 | TD Cowen | Buy |
| 2024-06-24 | 개시 | Exane BNP Paribas | Neutral |
| 2024-06-13 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-06-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-28 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-03-01 | 재개 | Goldman | Buy |
| 2023-12-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-11-17 | 개시 | Piper Sandler | Overweight |
| 2023-10-12 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-22 | 개시 | HSBC Securities | Hold |
| 2023-03-20 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-02-17 | 개시 | Citigroup | Sell |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-06 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2022-10-18 | 개시 | Evercore ISI | In-line |
| 2022-10-12 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2022-09-14 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 다운그레이드 | Bernstein | Mkt Perform → Underperform |
| 2022-01-27 | 재확인 | Citigroup | Sell |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2022-01-27 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-11 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-10-26 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-09-09 | 개시 | HSBC Securities | Hold |
| 2021-06-24 | 개시 | UBS | Neutral |
| 2021-05-14 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-26 | 다운그레이드 | Argus | Buy → Hold |
| 2021-01-20 | 개시 | Bernstein | Mkt Perform |
| 2020-12-08 | 개시 | Wells Fargo | Underweight |
| 2020-10-16 | 개시 | Berenberg | Buy |
| 2020-10-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-10-23 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2019-09-27 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-09-23 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-07-24 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2019-06-19 | 재확인 | BofA/Merrill | Neutral |
| 2019-04-23 | 업그레이드 | Argus | Hold → Buy |
| 2019-04-23 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2019-02-11 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-01-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-09-20 | 개시 | Atlantic Equities | Underweight |
| 2018-08-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-08-15 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2018-06-21 | 개시 | Morgan Stanley | Underweight |
| 2017-12-14 | 개시 | Deutsche Bank | Hold |
모두보기
킴벌리클라크 주식(KMB)의 최신 뉴스
Kimberly-Clark, Kenvue’s $48.7B deal among recent multibillion-dollar M&A - Manufacturing Dive
Kimberly-Clark transformation adds complexity and uncertainty, says Evercore - Investing.com
The Gamble Behind a Big Takeover of Tylenol’s Maker - The New York Times
Kimberly-Clark: Can The Kenvue Acquisition Erase The Decade Of Disappointment? (KMB) - Seeking Alpha
Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion deal - 101.3 KFDI
Kimberly-Clark acquires Kenvue for USD 48.7 billion to strengthen its leadership in personal care and health - Tissue Online North America
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn - Yahoo Finance
Kenvue Stock Rose 12% On Possible $48.7 Billion Acquisition by Kimberly-Clark - TIKR.com
This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue - The Daily Upside
Kenvue (KVUE) Soars 12% on $48.7-Billion Kimberly-Clark Merger - Insider Monkey
Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal - Yahoo Finance
Kimberly-Clark (NASDAQ:KMB) Sets New 52-Week LowTime to Sell? - MarketBeat
Kimberly-Clark to acquire Band-Aid, Neutrogena owner Kenvue for $48.7 billion - Storyboard18
Kimberly-Clark (KMB): Assessing Value After Recent 17% Share Price Slide - Yahoo Finance
iA Global Asset Management Inc. Sells 18,949 Shares of Kimberly-Clark Corporation $KMB - MarketBeat
Kimberly-Clark Stock Drops Premarket Even As Analysts, Retail Investors Turn Positive On $49B Kenvue Deal - Stocktwits
Kimberly-Clark to acquire Tylenol's parent company in nearly $49B deal - NPR
Kimberly-Clark Bets $48.7B on Health Giant Kenvue - Value The Markets
Kimberly-Clark Corporation $KMB Shares Bought by Atria Investments Inc - MarketBeat
Kimberly-Clark to buy Kenvue - The Arkansas Democrat-Gazette
These 2 Dividend Kings Are Combining in a $48.7 Billion Megadeal. Is It A Win-Win for Dividend Investors? - The Motley Fool
Can machine learning forecast Kimberly Clark Corporation recoveryEarnings Summary Report & High Accuracy Trade Signal Alerts - newser.com
Kimberly-Clark to acquire Kenvue, creating a $32 billion leader - PULPAPERnews.com
Is Kimberly Clark Corporation stock a buy in volatile marketsJuly 2025 Levels & Technical Entry and Exit Tips - newser.com
Kimberly-Clark buying Kenvue in $48.7 billion consumer brands deal - TelegraphHerald.com
Kimberly-Clark is taking Tylenol in $49 billion deal - Morning Brew
Kenvue’s Tylenol Litigation Overhang Doesn’t Dim ‘Generational Opportunity’ For Kimberly-Clark - Citeline News & Insights
Kenvue Shares Soar 16% After Inking $48.7B Deal With Kimberly-Clark - Stocktwits
Will Kimberly Clark Corporation stock outperform Dow Jones index2025 Short Interest & Fast Gaining Stock Reports - newser.com
Latham Advises on Financing for Kimberly-Clark’s Acquisition of Kenvue to Create a US$32 Billion Global Health and Wellness Leader - Legal Desire Media and Insights
The CEO Behind Kimberly-Clark’s $40 Billion Gamble on Tylenol MakerWSJ - The Wall Street Journal
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Kimberly-Clark to buy Kenvue in US$48.7 billion deal - Marketing-Interactive
Kimberly-Clark, Eaton Put Dealmakers on Cusp of $4 Trillion - Bloomberg.com
Kimberly-Clark Bets $50 Billion On Health And Beauty With Kenvue Deal - Finimize
Kimberly-Clark buys Kenvue; combined company expected to generate $32-billion a year - Yahoo News Canada
Kimberly-Clark to Acquire Kenvue - WWD
North Texas’ Kimberly-Clark To Acquire Tylenol Maker in $40B Deal - Dallas Innovates
Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal - BeautyMatter
Kimberly-Clark "considered all risks" before Tylenol deal - Axios
Factbox-Kenvue’s legal risks loom over planned acquisition by Kimberly-Clark - Yahoo Finance
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm - The New York Times
Kimberly-Clark acquires Neutrogena-owner Kenvue - FashionNetwork USA
Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue - The Wall Street Journal
Kimberly-Clark’s $50 billion leap into health and beauty tests investor faith - Reuters
Kimberly-Clark’s $50 billion leap into health and beauty tests investor faith By Reuters - Investing.com
Kenvue: Takeover by Kimberly-Clark Gives Shareholders a Lifeline - Morningstar
Kimberly-Clark Confirms Kenvue Acquisition Deal: Why It Is Buying the Tylenol Maker - International Business Times
Reports of ‘Click-to-Cancel’s Death May Be Premature - PYMNTS.com
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal - WTOP
킴벌리클라크 (KMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
2.14%
자본화:
|
볼륨(24시간):